Category - Feature

Feature

NeuroSense advancing potential paradigm shift in ALS therapy

NeuroSense Therapeutics (NASDAQ:NRSN) is developing a novel fixed dose combination of two FDA-approved drugs for a multi-targeted approach against the potential pathways responsible for ALS, or amyotrophic lateral...

June 21, 2022

Feature

QSAM Biosciences developing next-gen targeted radiopharmaceuticals for cancer

QSAM Biosciences (OTCQB:QSAM) began dosing bone cancer patients in a Phase 1 study in April 2022 with its next-generation radiopharmaceutical, CycloSam, which delivers the beta-emitting radioisotope, samarium-153, to...

June 14, 2022

Feature

Synlogic advancing novel biotherapeutics based on synthetic biology

Synlogic (NASDAQ:SYBX) is advancing a new class of biotherapeutics, known as Synthetic Biotics, targeting validated biology in rare metabolic and immunological diseases.

June 7, 2022

Feature

Iterion Therapeutics addressing multiple cancers with TBL1 inhibition

Closely held Iterion Therapeutics is employing a unique strategy with its lead asset, tegavivint, which is designed to bind to TBL1 (transducin beta-like protein one) and inhibit nuclear beta-catenin signaling and...

May 31, 2022

Feature

MindMed driving therapeutic potential of psychedelics for brain health disorders

MindMed (NASDAQ:MNMD; NEO:MMED) is advancing a pipeline of psychedelic and next generation drug candidates to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology.

May 24, 2022

Feature

Lanier Biotherapeutics joins Big Pharma advancing first-in-class Type 2 and non-Type 2 anti-inflammatory biologic

Closely held Lanier Biotherapeutics is pioneering a first-in-class Type 2 and non- Type2 anti-inflammatory biologic, LNR 125, as a new candidate targeting treatments commonly associated with Type 2 inflammation like...

May 17, 2022

Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.

May 10, 2022

Feature

Talking mental health with Chris Wang of Shimmer

As co-founder and CEO of Shimmer, a provider of a science-backed process to reduce stress and anxiety, Chris Wang took an early interest in social impact consulting at her first job with Bain & Co. But a close family...

May 3, 2022

Feature

Claritas Pharmaceuticals transforming nitric oxide therapy

Claritas Pharmaceuticals (TSXV:CLAS; OTC:CLAZF) is developing R-107, a liquid drug candidate that may hold the key to transforming nitric oxide therapy from its current gaseous inhalation method of delivery to...

April 26, 2022

Feature

In conversation with Dr. Murat Kalayoglu of Cartesian

As president and CEO of closely held Cartesian Therapeutics, Murat Kalayoglu, M.D., Ph.D., has made a smooth transition over the years from a board-certified ophthalmologist to a healthcare IT entrepreneur to a medical...

April 12, 2022

Category - Feature

Subscribe